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Abstract
Introduction: Breast cancer exhibits significant molecular, histological, and pathological diversity. Factors that
impact this heterogeneity are poorly understood; however, transformation of distinct normal cell populations of the
breast may generate different tumor phenotypes. Our previous study demonstrated that the polyomavirus middle T
antigen (PyMT) oncogene can establish diverse tumor subtypes when broadly expressed within mouse mammary
epithelial cells. In the present study, we assessed the molecular, histological, and metastatic outcomes in distinct
mammary cell populations transformed with the PyMT gene.
Methods: Isolated mouse mammary epithelial cells were transduced with a lentivirus encoding PyMT during an
overnight infection and then sorted into hormone receptor–positive luminal (CD133+), hormone receptor–negative
luminal (CD133−), basal, and stem cell populations using the cell surface markers CD24, CD49f, and CD133. Each
population was subsequently transplanted into syngeneic cleared mouse mammary fat pads to generate tumors.
Tumors were classified by histology, estrogen receptor status, molecular subtype, and metastatic potential to
investigate whether transformation of different enriched populations affects tumor phenotype.
Results: Although enriched mammary epithelial cell populations showed no difference in either the ability to
form tumors or tumor latency, differences in prevalence of solid adenocarcinomas and squamous, papillary,
and sebaceous-like tumors were observed. In particular, squamous metaplasia was observed more frequently
in tumors derived from basal and stem cells than in luminal cells. Interestingly, both molecularly basal and
luminal tumors developed from luminal CD133+, basal, and stem cell populations; however, luminal CD133− cells gave
rise exclusively to molecularly basal tumors. Tumors arising from the luminal CD133−, basal, and stem cell populations
were highly metastatic; however, luminal CD133+ cells generated tumors that were significantly less metastatic,
possibly due to an inability of these tumor cells to escape the primary tumor site.
Conclusions: Expression of PyMT within different mammary cell populations influences tumor histology, molecular
subtype, and metastatic potential. The data demonstrate that luminal CD133+ cells give rise to less metastatic tumors,
luminal CD133− cells preferentially establish basal tumors, and the cell of origin for squamous metaplasia likely resides
in the basal and stem cell populations.
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Introduction
The classification of breast cancer into several distinct
molecular and histological subtypes can provide infor-
mation to help guide patient therapy and predict
outcome [1, 2]. Tumors that retain histological and mo-
lecular attributes of normal tissue are considered well
differentiated and are generally less aggressive and cor-
relate with better patient prognosis. In contrast, the loss
of normal tissue structure and the dysregulation of genes
involved in modulating growth and differentiation in-
dicate transition of the disease into a more advanced
stage [3]. A better understanding of tumor etiology
and processes that control the transition between early
and advanced states of breast cancer may improve
strategies for detection, treatment, and prevention of
the disease.
How a particular cell responds to a transforming
event, its susceptibility for malignant progression, and
its role in establishing a tumor’s histological and mo-
lecular fate are poorly understood. The mammary gland
is a complex tissue composed of two distinct cell line-
ages, the luminal epithelium and myoepithelium, with
each lineage encompassing a hierarchy of cells at various
states of differentiation [4, 5]. When a normal cell is
transformed, preexisting signaling networks intrinsic to
that particular cell type may become dysregulated and
contribute to tumor growth and progression. For ex-
ample, tumors classified as a hormone-receptor positive
subtype express estrogen receptor (ER or Esr1) and are
generally dependent on estrogen for growth, recapitulat-
ing characteristics of a subset of normal, luminal epithe-
lial cells found in the breast [6]. Molecular similarities
are also observed between other normal cell populations
and cancer subtypes. Mammary stem cells have a gene
expression signature similar to spindloid and claudin-
low tumors [7–9], whereas the molecular signature of
normal luminal progenitors is associated with basal-like
breast cancer [8]. Even differentiated mammary epithe-
lial cells (MECs) share molecular features with a cancer
subtype. Tumors histologically classified as lipid-rich
carcinoma of the breast express metabolic and differenti-
ation markers observed in alveolar cells, the milk-
producing cells of the mammary gland [10–12]. These
molecular associations suggest that tumors can arise
from different cell populations and maintain signaling
networks of their cell of origin.
Although transforming events within a cell may initi-
ate and drive the process of tumor progression, these
events do not necessarily establish a tumor’s histological
or molecular fate. Data derived from The Cancer
Genome Atlas demonstrate that major oncogenic drivers
and tumor-associated mutations are broadly represented
among breast cancer subtypes, suggesting that diverse
mechanisms contribute to a tumor’s phenotype [13].
Such mechanisms may include cell-intrinsic networks
acquired from the cell of origin. In support of this, sev-
eral studies have demonstrated that normal cell types
can respond to the same oncogenic pathway in unique
ways. Ince et al. used different cell culture conditions to
enrich for either luminal-like or myoepithelial-like hu-
man breast cell populations [14]. Both populations were
subsequently transformed with a common set of onco-
genic drivers. When transplanted, each precursor cell
population generated a distinct tumor phenotype, with
notable differences in tumor histology and metastasis.
The myoepithelial-like cells established tumors similar
to squamous carcinoma of the breast, whereas the
luminal-like cells generated papillary adenocarcinomas
[14]. Other studies with mouse mammary tumor models
have also supported a role for the cell of origin in con-
trolling tumor fate. Differences in tumor phenotype were
observed when a Brca1 mutation was induced in differ-
ent normal cell populations. Conditional Brca1 loss of
function targeted to the basal compartment using
Keratin-14-Cre Brca1fl/fl p53+/− mice established tu-
mors that were primarily adenosquamous carcinomas
and adenomyoepitheliomas. In contrast, disruption of
Brca1 in luminal progenitors using Blg-Cre Brca1fl/fl
p53+/− mice resulted in ductal carcinomas with a
basal-like molecular subtype [15]. These studies sug-
gest that intrinsic differences between cell populations
may influence the histopathology of the tumors they
generate.
The polyomavirus middle T antigen (PyMT) oncogene
has been used extensively in mice to model breast
cancer [16, 17]. In these models, PyMT drives trans-
formation of MECs by signaling through several path-
ways, including Src, Ras, and phosphoinositide 3-kinase
[18–21], resulting in a phenotype similar to ErbB2/Neu-
induced tumors [7, 22, 23]. Transgenic mice that express
PyMT under control of the promoter derived from the
long terminal repeat (LTR) of the mouse mammary
tumor virus (MMTV) develop mammary tumors that
undergo progressive transition from precancerous le-
sions to late-stage malignant tumors and exhibit a
high frequency of metastasis [16, 24, 25]. Tumor pro-
gression is marked by a loss of both myoepithelial
cells and ER+ luminal cells [24], and a concomitant
expansion of cells expressing the luminal progenitor
marker CD61 [26]. Through intrinsic gene set analysis
and hierarchical clustering of gene expression profiles,
MMTV-PyMT tumors have been classified within the
luminal subgroup [7, 9]. In addition, a close associ-
ation between the molecular signature derived from
luminal progenitors and MMTV-PyMT tumors has
been described [9]. Similar to other mouse models
that function through ErbB/Ras signaling proteins, the
predominant tumor histology in the MMTV-PyMT
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model is solid adenocarcinoma. However, varied histo-
pathology is observed, with approximately 30 % of tu-
mors having papillary, glandular, or acinar features
and 10 % exhibiting either adenosquamous, pilar, or
type P histology [22].
These data demonstrate that the MMTV-PyMT model
can establish tumors with both a luminal phenotype and
diverse histopathology. It is unknown whether these
characteristics are a result of the activity of the MMTV
LTR within a particular cell type or through unique
transforming activity of the PyMT oncogene. Because
the MMTV LTR is widely active in mammary epithelium
and drives expression at early stages of postnatal devel-
opment [27–29], it is difficult to identify the cell of ori-
gin for tumors in this model. In order to assess how
cellular context affects tumor progression, the PyMT
oncogene has been targeted to various MEC populations
by uncoupling expression of the oncogene from the
MMTV LTR. For example, virus-based approaches have
been used to express PyMT either ubiquitously in all
mammary cell populations or specifically within distinct
cell types, and these studies have shown that tumor hist-
ology and molecular subtype can vary as a result of the
targeting approach [12, 30, 31]. The restricted expression
of PyMT in the keratin 6 (K6) mammary cell population
resulted in tumors with predominantly papillary and cys-
tic histology and a distinct normal-like molecular sub-
type, representing a phenotype dissimilar to what has
been observed in the MMTV-PyMT mouse model [27].
In contrast, non-cell-type–specific expression of PyMT
in MECs using the ubiquitous elongation factor 1 alpha
(EF1α) promoter generated tumors with diverse hist-
ology, including a high frequency of adenosquamous
carcinomas and the occurrence of a unique lipid-rich
carcinoma [12]. In addition, this model produced tumors
that classified within both luminal and basal molecular
subgroups [12]. In the present study, we extended upon
these studies by evaluating the latency, histopathology,
molecular subgroup, and metastatic potential of tumors
derived from four different fluorescence-activated cell
sorting (FACS)-enriched MEC populations. The results
suggest that the originating cell population influences
several tumor characteristics and further implicates a
cell residing predominantly in the basal and stem cell
compartment as the cellular origin for squamous
metaplasia.
Methods
Mice
FVB/NJ mice were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA) and maintained in a pathogen-
free facility. The University of Utah Institutional Animal
Care and Use Committee approved mouse handling and
procedures.
Generation of mouse mammary tumors
MECs were collected from 8–10-week-old FVB/NJ mice
as described previously [12]. Then, freshly isolated MECs
were infected with EF1α-PyMT-ZsGreen lentivirus over-
night at 37 °C as described previously [12]. Following
infection, cells were washed five times with Hanks’
balanced salt solution (HBSS; Gibco/Thermo Fisher
Scientific, Grand Island, NY, USA) and incubated with
0.05 % trypsin-ethylenediaminetetraacetic acid (EDTA;
Gibco/Thermo Fisher Scientific, Grand Island, NY, USA)
to isolate single cells. Trypsin was inactivated with
MEC media [12], and cell clumps were removed by
straining MECs through a 40-μm cell strainer (Falcon;
Fisher Scientific, Pittsburgh, PA, USA). MECs were then
resuspended in wash buffer (HBSS + 2 % fetal bovine
serum; HyClone Laboratories/GE Healthcare, Logan, UT,
USA) and kept on ice for antibody staining and FACS.
Staining consisted of six tubes: (1) no antibody control,
(2) CD24-V450 control, (3) CD49f-phycoerythrin (CD49f-
PE) control, (4) CD133-allophycocyanin (CD133-APC)
control, (5) 7-amino-actinomycin D (7-AAD) control, and
(6) CD24-V450/CD49f-PE/CD133-APC/7-AAD sample.
During antibody staining, control tubes contained 5 × 104
cells and the sample tube contained 20 × 106 cells resus-
pended in 200 μl of wash buffer. All antibodies were ob-
tained from BD Pharmingen (San Diego, CA, USA) and
were used at a 1:100 dilution. After the primary antibodies
were added, cells were incubated on ice for 15 minutes.
Following incubation, cells were washed with 1 ml of wash
buffer and centrifuged at 1000 × g for 2 minutes. Stained
MECs were then resuspended in wash buffer and sorted
into luminal CD133+, luminal CD133−, basal, and stem
cell populations as described previously [32–35] on a BD
FACSAria Cell Sorter using FACSDiva version 6.1.3
software for analysis (BD Biosciences, San Jose, CA,
USA). Isolated MEC populations were kept on ice
until transplantation.
For each transplantation, 1 × 105 untransduced and
unsorted MECs were mixed with 2 × 104 transduced lu-
minal CD133+, luminal CD133−, basal, or 5 × 103 stem
enriched MECs. MECs were then resuspended in 10 μl
of Matrigel (BD Biosciences, San Jose, CA, USA) by
transplantation, and the Matrigel cell mixture was
injected into the fourth cleared inguinal mammary fat
pad of 3-week-old FVB/NJ mice. Only a single fat pad
was injected per mouse. Tumor growth was monitored,
and tumors were collected upon reaching 2 cm in diam-
eter. Once tumors were harvested, viable cells were col-
lected using the same protocol for MEC isolation and
then frozen in freeze media as described previously [12].
Portions of the tumors were also flash-frozen for RNA
isolation using a Qiagen RNeasy kit (Qiagen, Valencia,
CA, USA), and additional tumor fragments were proc-
essed for paraffin embedding.
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Infection, cell sorting, and transplantation experiments
were performed over two rounds. Each time, 10 trans-
plants were performed per sorted MEC population, for a
total 20 transplants per group.
Antibody staining and histology
Portions of transduced and FACS-sorted MECs were used
to quantify basal and luminal cell enrichment. For each
isolated population, 1 × 104 MECs resuspended in 200 μl of
wash buffer were centrifuged (Cytospin 4 Cytocentrifuge;
Thermo Scientific, Hudson, NH, USA) onto slides (Shan-
don Cytoslide; Thermo Scientific, Hudson, NH, USA)
at 900 rpm for 10 minutes. Cytospun cells were then
incubated with fixative solution (4 % paraformaldehyde in
phosphate-buffered saline [PBS]) for 15 minutes and
washed five times with PBS for 5 minutes each. Fixed cells
were permeabilized for 10 minutes with 0.2 % Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) in PBS, washed with
1 % bovine serum albumin (BSA; EMD Millipore, Billerica,
MA, USA) in PBS, and blocked with 1 % BSA in PBS
for 10 minutes. Cells were then incubated with primary
antibodies against keratin 14 (K14, 1:400 dilution, rabbit,
PRB-P-100; Covance, Princeton, NJ, USA) and keratin 8
(K8, 1:50 dilution, rat, TROMA-I; Developmental Studies
Hybridoma Bank, Iowa City, IA, USA) for 1 h at room
temperature. Following incubation, slides were washed with
1 % BSA in PBS and stained with 4′,6-diamidino-2-pheny-
lindole dihydrochloride and secondary antibodies Alexa
Fluor 594 chicken anti-rat immunoglobulin G (IgG, 1:1000
dilution; Invitrogen/Life Technologies, Carlsbad, CA, USA)
and Alexa Fluor 488 goat anti-rabbit IgG (1:1000 dilution;
Invitrogen/Life Technologies, Carlsbad, CA, USA).
Paraffin-embedded tumor samples were processed and
subjected to hematoxylin and eosin (H&E) staining, ESR1
immunohistochemistry (IHC), and cytokeratin staining as
described previously [12]. The following primary anti-
bodies were used: K14 (1:400 dilution, rabbit, PRB-P-100;
Covance), K8 (1:50 dilution, rat, TROMA-I; Developmen-
tal Studies Hybridoma Bank, Iowa City, IA, USA), and
ESR1 (1:200 dilution, MC-20, sc-542; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Secondary antibodies
included Alexa Fluor 594 chicken anti-rat IgG (1:1000
dilution; Invitrogen/Life Technologies, Carlsbad, CA,
USA), Alexa Fluor 488 goat anti-rabbit IgG (1:1000 dilu-
tion; Invitrogen/Life Technologies, Carlsbad, CA, USA),
and biotin-SP-conjugated protein (1:1000 dilution; Jackson
ImmunoResearch Laboratories, West Grove, PA, USA).
All immunofluorescence imaging was performed on
an Olympus IX81 microscope (Olympus, Tokyo, Japan)
using a Hamamatsu Photonics ORCA-ER camera (Ha-
mamatsu Photonics, Hamamatsu City, Japan). Fluores-
cence image recording and processing were performed
using SlideBook 64 version 5.0.0.24 software (Intelligent
Imaging Innovations, Denver, CO, USA). Slides
processed for IHC and H&E staining were imaged on an
Olympus BX50 microscope with a Canon EOS Rebel
XSI camera using EOS imaging software (Canon, Mel-
ville, NY, USA). Any changes in contrast and brightness
were performed using Photoshop CS4 software (Adobe
Systems, San Jose, CA, USA) on entire images to en-
hance appearance without altering image content.
In vitro and in vivo assessment of tumor growth with
estrogen receptor inhibition
For in vitro dose–response studies, tumor cells and
MECs were isolated using the same tissue dissociation
protocol as described above. Single cells were sus-
pended in Matrigel (BD Biosciences, San Jose, CA,
USA) and 10 μl of a cell/Matrigel mixture was plated
per well in a 96-well plate (Costar; Corning Life
Sciences, Oneonta, NY, USA). 4-Hydroxytamoxifen
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
ethanol and serially diluted in MEC media. Cells were
dosed with 100 μl of media containing drug or ve-
hicle control for 48 h. Media with drug or vehicle
control was refreshed every 24 h. Each drug concen-
tration was tested in triplicate. Cell viability was mea-
sured using the ATPlite assay (PerkinElmer, Waltham,
MA, USA) according to the manufacturer’s instruc-
tions and normalized to vehicle control.
Tumor growth dependence on estrogen was tested in
vivo by conducting an additional primary cell infection,
FACS, and transplantation experiments as described
above. Ovaries were removed from all mice that received
cell transplants, as described previously [36]. Ten surger-
ies were performed per infected and sorted population.
Microarray analysis
Flash-frozen tumors were randomly selected from each
of the tumor groups for RNA extraction and microarray
analysis. Total RNA was isolated using the Qiagen
RNeasy kit.
To perform supervised hierarchical clustering, all steps of
microarray processing, data filtering and normalization,
and analysis were performed as described previously [12].
Batch adjustment was performed in two batches. A dataset
generated by Herschkowitz et al. was treated as one batch
(Gene Expression Omnibus [GEO] accession number
[GEO:GSE3165]) [7], and data generated at the Huntsman
Cancer Institute (HCI) was treated as a second batch.
The HCI microarray dataset has been deposited in the
National Center for Biotechnology Information GEO
database under accession number [GEO:GSE64453].
To perform unsupervised hierarchical clustering,
quantile-normalized, log-scaled microarray intensity data
were hierarchically clustered in R using Ward’s method.
The resulting dendrogram revealed a marked batch
effect related to the date on which the arrays were
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processed. Each class of samples (luminal CD133−,
luminal CD133+, basal, and stem) were adjusted for
batch effect separately using the ComBat procedure
[37] and then recombined. Differential expression analysis
comparing the luminal CD133− samples with the
remaining samples identified 1111 microarray probes
representing 1046 unique genes showing at least two-
fold differential expression at an adjusted p value <0.05
(p value by t test with adjustment using the Benjamini-
Hochberg method).
Assessment of tumor metastasis
As described above, transplantation experiments were
performed twice for each transduced and enriched MEC
population. Lung metastasis for the first round was
assessed by H&E staining. Lung tissue processing and
staining were performed as described above. Paraffin-
embedded lungs were serially sectioned at 10 μm, and
every fifth slide was stained and examined for metastasis.
For the second round of transplants, lung metastases
were analyzed by fluorescence imaging after lungs were
flattened between two glass slides. Slides were imaged as
described above, and numbers of unique metastatic sites
and tumor areas were quantified using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Prevalence of lung metastases and numbers of metastatic
foci were consistent over two rounds of transplants.
To quantify circulating tumor cell (CTC) numbers, fresh
whole blood was collected by cardiac puncture immediately
after mice were killed according to University of Utah–
approved Institutional Animal Care and Use Committee
procedures. CTCs were isolated for FACS analysis as de-
scribed previously from mice bearing primary tumors, as
well as from no-tumor control mice [38]. CTCs expressing
ZsGreen were detected by analyzing cells using a FACScan
cytometer (BD Biosciences, San Jose, CA, USA), and results
were quantified using FlowJo software (Tree Star, Ashland,
OR, USA). Owing to low numbers of CTCs present within
isolated whole blood, the ZsGreen-positive threshold was
set at 0.05 % of no-tumor control background signal. This
threshold was then used as a baseline for detecting CTCs
in tumor-bearing mice. All CTC values were then normal-
ized to no-tumor control background signal.
Tail vein injections were performed to assess the ability of
tumor cells to colonize the lungs after introduction into the
bloodstream. Single cells were isolated from primary tu-
mors using the same procedure employed for MEC isola-
tion. Cells were then resuspended in HBSS at 10 × 106 cells/
ml. A quantity of the HBSS/cell mixture (250 μl; 2.5 × 105
cells) was injected into the lateral tail veins of 8–12-week-
old FVB/NJ mice. Cells isolated from individual tumors
were injected into five mice each. Twenty days postinjec-
tion, mice were killed and tumor lung foci numbers were
quantified by fluorescence imaging with ImageJ software.
Analysis of PyMT expression in transduced mammary
epithelial cells
Freshly isolated MECs were infected in suspension over-
night and then transferred to adherent culture in MEC
media the following day. Separate plates of cells were ana-
lyzed for ZsGreen and PyMT expression each day for
5 days. Protein lysates were prepared for simple Western
blot analysis to detect PyMT expression, and cells were
analyzed for ZsGreen expression by flow cytometry. For
cytometry, cells were washed with PBS, lifted with 0.25 %
trypsin-EDTA (Gibco/Thermo Fisher Scientific), fixed in
2 % paraformaldehyde, and resuspended in wash buffer on
ice. Single cells were isolated by straining them through a
40-μm cell strainer (Falcon; Fisher Scientific) and immedi-
ately analyzed with a BD LSR II flow cytometer (BD
Biosciences, San Jose, CA, USA) for ZsGreen expression.
Real-time quantitative PCR analysis
RNA was isolated from freshly sorted MECs or flash-
frozen tumors using the Qiagen RNeasy Mini Kit. For
cDNA synthesis from tumor RNA, 1 μg of total RNA
was reverse-transcribed using the iScript Reverse
Transcription Supermix for real-time quantitative PCR
(RT-qPCR) synthesis kit (Bio-Rad Laboratories, Hercules,
CA, USA) according to the manufacturer’s instructions.
For sorted MECs, cDNA was synthesized from 20 ng of
total RNA via reverse transcription, followed by preampli-
fication with pooled PrimeTime assays (Integrated DNA
Technologies, Coralville, IA, USA) for genes of inter-
est using the Qiagen RT2 PreAMP cDNA Synthesis
Kit. Genes investigated were K8 (assay identification:
Mm.PT.58.6862465), K14 (Mm.PT.58.43652691), pro-
gesterone receptor (Pgr; Mm.PT.58.10254276), Esr1
(Mm.PT.58.8025728), p63 (Mm.PT.58.13970687), Slug
(Mm.PT.58.43645779), c-Kit (Mm.PT.56a.33701407),
and glyceraldehyde 3-phosphate dehydrogenase (Gapdh;
Mm.PT.39a.1) for reference. RT-qPCRs were performed
in 20-μl volumes using 2× SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) in a
Roche LightCycler96 system (Roche Applied Science,
Indianapolis, IN, USA). The primers for PyMT and the
reference gene, Rplp0, have been described previously [12].
Each sample was normalized to the reference gene, sorted
MEC cycle threshold change (ΔCT) values were compared
with a control population of unsorted MECs, and relative
fold induction level for each sorted population/tumor was
calculated using the 2−ΔΔCt method [39].
Simple Western blot analysis
Using a PowerGen 125 sawtooth homogenizer (Fisher
Scientific), protein lysates were prepared from flash-frozen
tumors using Pierce IP Lysis Buffer (25 mM Tris∙HCl,
pH 7.4, 150 mM NaCl, 1 % Nonidet P-40, 1 mM EDTA,
5 % glycerol; Pierce Biotechnology/Thermo Scientific,
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Rockford, IL, USA) with 10 mM sodium pyrophosphate
tetrabasic (Sigma-Aldrich, St. Louis, MO, USA), 1 mM so-
dium orthovanadate (Sigma-Aldrich, St. Louis, MO,
USA), Phosphatase Inhibitor Cocktails 2 and 3 (Sigma-Al-
drich, St. Louis, MO, USA), and Mammalian ProteaseArr-
est cocktail (G-Biosciences, St. Louis, MO, USA). Lysates
from cultured cells were prepared without pyrophosphate
tetrabasic and sodium orthovanadate. Protein was quanti-
fied using a DC Protein Assay Kit (Bio-Rad Laboratories,
Hercules, CA, USA) and a DU 730 UV/VIS spectropho-
tometer (Beckman Coulter, Fullerton, CA, USA).
Simple Western blot analyses were performed as
instructed by the ProteinSimple user manual. Briefly, cell
lysates were mixed with a master mix (ProteinSimple,
San Jose, CA, USA) to a final concentration of 1× sample
buffer, 1× fluorescence molecular weight marker, and 40
nM dithiothreitol. Following 5-minute denaturation at
95 °C, the samples, blocking agent, primary antibodies,
horseradish peroxidase–conjugated secondary antibody,
and chemiluminescence substrate were dispensed into
the designated wells of the 384-well plate. Automated
separation electrophoresis and immunodetection were
performed using a ProteinSimple WES instrument. All
antibodies were diluted in the antibody diluent II (Protein-
Simple, San Jose, CA, USA) and incubated with the
protein for 10–15 minutes. A luminol-peroxide mixture
(ProteinSimple, San Jose, CA, USA) was used to generate
chemiluminescence, which was captured with a charge-
coupled device camera. The resulting digital image was
analyzed with Compass software (ProteinSimple, San Jose,
CA, USA), and quantified data were reported as molecular
weight, signal and peak intensity, and area under the curve.
The following antibodies used were obtained from
Cell Signaling Technology (Danvers, MA, USA): β-actin
(13E5, 1:50 dilution, catalog number 4970P), AKT
(C67E7, 1:50 dilution, catalog number 4691P), extracel-
lular signal-regulated kinase 1/2 (ERK1/2; 137 F5, 1:50
dilution, catalog number 4695P), SRC (36D10, 1:100 di-
lution, catalog number 2109S), phospho-AKT (Thr308,
C31E5E, 1:25 dilution, catalog number 2965S), phospho-
ERK1/2 (Thr202/Tyr204, dilution 1:50, catalog number
4370P), and phospho-SRC (Tyr527, 1:50 dilution, catalog
number 2105P). The following antibodies were obtained
from Santa Cruz Biotechnology(Santa Cruz, CA, USA):
hemagglutinin probe (Y-11, 1:12.5 dilution, catalog num-
ber sc-805) and GAPDH (FL-335, 1:1500 dilution, cata-
log number sc-25778).
Statistical analysis
All data analyses were performed in using GraphPad
Prism 6.0d software (GraphPad Software, La Jolla, CA,
USA). For each analysis, specific statistical tests are indi-
cated in the figure legends.
Results
FACS-enriched mammary cell populations expressing
PyMT develop tumors with equivalent latency
The degree of tumor heterogeneity in PyMT-based
mouse models is associated largely with stage of pro-
gression [24], mouse strain [40–42], and the approach
used to target the oncogene to mammary epithelium
[12, 27, 30, 31]. To extend upon these studies, we asked
whether PyMT oncogenesis within specific luminal, basal,
and stem cell populations would affect tumor latency,
pathology, metastasis, and molecular subgroup. The ex-
perimental design for this analysis was to transduce pri-
mary MECs overnight with the EF1α-PyMT-ZsGreen
lentivirus [12], followed by FACS enrichment of specific
cell populations and transplantation with an excess of un-
infected and unsorted MECs (Fig. 1a). This technique was
designed to ensure that primary cells would be ex-
posed to similar conditions during ex vivo procedures
and to provide comparable cellular environments for
tumor development.
In order to determine whether expression of the lenti-
viral transgenes would affect the cell sorting procedure,
we assessed ZsGreen fluorescence and PyMT protein
levels in MECs for 5 days following transduction with
the EF1α-PyMT-ZsGreen lentivirus (Additional file 1,
panel a). Only 2 % of cells were ZsGreen-positive at 24 h
after transduction, whereas 30 % were positive at day 5.
In addition, PyMT protein expression was nearly un-
detectable until day 3 (Additional file 1, panels b and c).
These data suggest that the lentiviral genes would not
affect cell sorting within 24 h after transduction.
Freshly isolated primary MECs were infected with the
EF1α-PyMT-ZsGreen lentivirus overnight in suspension
[12] and then stained and sorted for the cell surface pro-
teins CD24, CD49f, and CD133, which are markers
known to delineate luminal, basal, and stem cell popula-
tions [34, 35]. Infected cells were not gated on ZsGreen,
owing to the low level of expression at 24 h posttrans-
duction. In accordance with published studies, luminal,
basal, and stem cells were isolated based on their expres-
sion of CD49f and CD24 (Fig. 1b) [32, 33, 35]. The
luminal cell population was further separated into hor-
mone receptor–positive and hormone receptor–negative
fractions by expression of CD133 (hereinafter called
luminal CD133+ and luminal CD133−, respectively)
(Fig. 1b) [34]. We next verified that enriched popula-
tions contained the expected keratin markers by
evaluating each population for the expression of lu-
minal cell-specific K8 and basal cell-specific K14 by
immunofluorescence (Fig. 1c) [43]. As expected, the
representative population markers were enriched in
the appropriate groups (Fig. 1d) [32–35]. Interestingly,
approximately 15 % of luminal CD133− cells and 33 % of
enriched stem cells were positive for both K8 and K14,
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Fig. 1 (See legend on next page.)
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suggesting the presence of a bipotent progenitor popu-
lation in these groups [44–47]. In addition, expression
levels of K8, K14, Esr1, the progesterone receptor (Pgr),
transcription factors (p63 and Slug), and tyrosine-
protein kinase (c-Kit) RNA were measured in each
population by RT-qPCR (Fig. 1e). The gene expression
patterns we observed confirmed the enriched expres-
sion of hormone receptors Esr1 and Pgr within the lu-
minal CD133+ population [34], whereas the stem cell
markers p63 and Slug were highly expressed in the
enriched stem cell population [9, 48]. Although both
basal and stem cell populations expressed K14 protein
(Fig. 1c), the mRNA was expressed in basal cells at a
level similar to that of unsorted MECs, suggesting a
difference in the transcriptional regulation of this gene
between basal and stem cell populations.
To assess tumor formation and progression from each
subpopulation, transduced luminal CD133+, luminal
CD133−, basal, and stem cells were individually trans-
planted into cleared mouse mammary fat pads. Each
enriched MEC population was cotransplanted with un-
sorted and untransduced MECs to provide a similar in
vivo environment for outgrowth and to minimize the
potential for transdifferentiation effects [49]. Tumors
arose from each enriched MEC population, and no stat-
istical difference in average tumor latency or tumor-free
survival was observed (Fig. 1f ), demonstrating that all
enriched MEC populations have the capacity to undergo
transformation and generate tumors. Also, no difference
in tumor latency was observed when transduced MECs
were transplanted into ovariectomized mice, demon-
strating that each cell population can establish tumors
independent of systemic hormones (Additional file 2,
panel b). Moreover, the short tumor latency suggests
that transformation is rapid and may be independent of
acquired mutations, which is also consistent with the
observation that three-dimensionally cultured MECs in-
fected with a PyMT-expressing lentivirus exhibit a trans-
formed phenotype within 2 weeks [12].
Expression of PyMT mRNA and AKT, SRC, and ERK
proteins was analyzed in 31 tumors to assess the vari-
ability of the PyMT signaling pathway between tumors.
Similar to previous findings [12], the expression of
PyMT mRNA was variable in tumor samples (Additional
file 3, panel a). However, the average expression of
PyMT in tumors was not significantly different between
tumors arising from the four cellular origins (Fig. 1g)
[12]. Furthermore, protein analysis demonstrated that
AKT, ERK, and SRC activation was not significantly
different between tumors (Fig. 1h and Additional file 3,
panels b–d). These data suggest that PyMT expression
and signaling are similar in tumors arising from different
MEC populations.
Enriched mammary epithelial cell populations establish
tumors with broad histopathology
We next analyzed the histology of tumors originating
from each of the enriched MEC populations. We clas-
sified tumors by H&E staining and cytokeratin expres-
sion and identified the following histologies: acinar,
papillary, solid adenocarcinoma, squamous, lipid-rich,
and sebaceous-like (Fig. 2a–f, Table 1). The frequency
of a specific histology was quantified by estimating its
area in two or three different sections per tumor
(Fig. 2g–k). Data are presented as the total percentage
area of a histological feature in each tumor (Fig. 2g–k)
(See figure on previous page.)
Fig. 1 A model to assess the influence of the cell of origin on tumor phenotype. a Freshly isolated mammary epithelial cells (MECs) were transduced
with the EF1α-PyMT-ZsGreen lentivirus, sorted into distinct populations by fluorescence-activated cell sorting (FACS), and transplanted into the cleared
mammary fat pads of syngeneic mice. b Transduced MECs were sorted into basal, luminal, and stem cell populations based on the expression of
the cell surface markers CD49f and CD24 (right). Luminal cells were further sorted according to CD133 expression into hormone receptor–positive
(CD133+) and hormone receptor–negative (CD133−) populations (left). The collected populations are indicated by red gates. APC allophycocyanin,
PE phycoerythrin. c FACS-enriched populations were evaluated for expression of basal keratin 14 (K14; red), luminal keratin 8 (K8; green), and
4′,6-diamidino-2-phenylindole dihydrochloride (blue) by immunofluorescence (scale bar = 20 μm). Inset shows representative K14/K8
double-positive cells from the stem cell enriched population (scale bar = 10 μm). d Quantification of the cytokeratin profile for each MEC
subgroup (n = total number of cells imaged). e Real-time quantitative PCR (RT-qPCR) quantification of relative differences in cytokeratin (K8,
K14), hormone receptor (progesterone [Pgr], estrogen receptor [Esr1]), transcription factor (p63, Slug), and tyrosine-protein kinase (c-Kit) RNA
expression levels between sorted MEC populations normalized to the GAPDH housekeeping gene. Expression levels were compared (by t test)
with RNA from unsorted controls (dashed line). *p < 0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001; ^expression values for p63 and Slug in the luminal
CD133+ population could not be determined, as amplification only rarely occurred below 40 cycles. Each data point is a mean ± SEM for triplicate
qPCR reactions from three independent cDNA synthesis/preamplification reactions (n = 9). f Kaplan-Meier curves of mice receiving orthotopic
transplants of distinct MEC subgroups. Mice were killed when tumors reached 2 cm in diameter (n = number of mice). g RT-qPCR quantification of relative
PyMT mRNA expression levels in averaged luminal CD133+ cell, luminal CD133− cell, basal cell, and stem cell tumors normalized to the Rplp0
housekeeping gene. No significant differences between tumor groups were detected (by t test, n = number of tumors). h Average ratio of
phosphorylated (pAKT) to AKT, phosphorylated extracellular signal-regulated kinase (pERK) to ERK, and phosphorylated SRC (pSRC) to Src
protein expression in luminal CD133+, luminal CD133−, basal, and stem cell tumors normalized to the β-actin. No significant differences
were detected between tumor groups (by analysis of variance for multiple comparisons)
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and as the predominant tumor histology of each tumor
(Additional file 4). Tumors that produced lung metastases
and those used for microarray analysis are also indicated.
Several trends became apparent. First, histologies were
not associated with ERK, AKT, or SRC phosphorylation
levels, suggesting that histopathology is uncoupled from
Fig. 2 Analysis and prevalence of histology in tumors derived from mammary epithelial cell (MEC) populations. a through f Representative
images of hematoxylin and eosin and cytokeratin staining of tumor histologies: acinar (a), papillary (b), solid adenocarcinoma (c), squamous (d),
lipid rich (e), and sebaceous-like (f). Immunofluorescence staining was performed for basal keratin 14 (K14; red) and luminal keratin 8 (K8; green)
(scale bar = 100 μm). ZsGreen fluorescence was not detected in the processed sections. Histological area per tumor was derived from luminal
CD133+ cells (g), luminal CD133− cells (h), basal cells (i), and stem cells (j). Boxes above each column indicate tumors that were used for microarray
analysis. Red boxes = basal subgroup; green boxes= luminal subgroup. Black circles mark tumors that were metastatic. k Average area of histology per
MEC group (unpaired t test; n = number of tumors). l Representative images of estrogen receptor (ESR1) staining, including negative (left panel) and
positive staining (right panel) (scale bar = 50 μm; n = number of tumors). m Quantification of ESR1 staining per MEC group (two proportion z test).
n Quantification of ESR1 staining per histological specimen (two proportion z test). *p < 0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001
Drobysheva et al. Breast Cancer Research  (2015) 17:132 Page 9 of 17
PyMT activity (Additional file 5, panel a). Second, al-
though papillary features were observed in tumors de-
rived from all cell types, they were significantly more
prevalent in tumors arising from luminal CD133+ cells
than in the stem cell–enriched population (Fig. 2k).
Next, the predominant histology generated by luminal
CD133− cells was solid adenocarcinoma, whereas basal
and stem cell–enriched populations established more
squamous tumors (Fig. 2k and Additional file 4). Finally,
several rare tumor types originated from specific
MEC populations. Lipid-rich tumors arose primarily
from the luminal CD133+ cell population, whereas
sebaceous-like carcinomas developed primarily from
basal and stem cells (Fig. 2k and Additional file 4).
Thus, each MEC-enriched population generated tu-
mors with a broad but distinct spectrum of histo-
logical subtypes.
ESR1 is a standard clinical marker used to guide a pa-
tient’s course of treatment and predict clinical outcome
[50]. ESR1 IHC staining was used to determine if any
enriched MEC subgroups developed tumors with exten-
sive ESR1-positive (ER+) cells, as defined by strong nu-
clear staining (Fig. 2l) in 20 % or more of tumor cells.
Surprisingly, all of the enriched MEC populations gave
rise to ER+ tumors, and luminal CD133+ cells generated
the highest proportion of ER+ tumors (Fig. 2m). Most
ER+ tumors exhibited either papillary or acinar hist-
ology, whereas few squamous tumors stained positive
for ESR1 (Fig. 2n). These observations are consistent
with previous reports that ER+ status appears to be as-
sociated with well-differentiated tumor histologies in
PyMT oncogene-driven tumors and is less prevalent in
tumors that are poorly differentiated [24]. Although ER+
tumors were observed, their hormone dependence was
not apparent. Cells isolated from both ER+ and ER− tu-
mors exhibited similar in vitro sensitivity to tamoxifen,
and no difference in tumor latency was observed when
transduced MECs were transplanted into ovariectomized
mice (Additional file 2). Similar to these results, both
the expression of Esr1 in tumor cells and lack of
estrogen-dependent growth were observed when
PyMT was targeted to mammary glands through intra-
ductal injection of a modified avian retroviral vector
[31]. Thus, Esr1 expression and estrogen-dependent
growth appear uncoupled in virus-based PyMT tumor
models.
Luminal CD133− mammary epithelial cells give rise to an
exclusively basal subgroup mammary tumors
We next tested whether MEC populations influenced
the molecular classification of the tumors they generate.
Tumors derived from each MEC population were classi-
fied by hierarchical analysis of microarray gene expres-
sion data. This classification method has previously been
used to cluster tumors from a variety of mouse models
into basal and luminal subgroups [7]. We analyzed be-
tween 6 and 11 tumors generated from each enriched
MEC population. An intrinsic 669-gene set consisting of
genes differentially expressed in mouse tumors repre-
senting basal and luminal subgroups was used to deter-
mine the molecular classification [7], and gene set
expression data were hierarchically clustered with 12
mouse models of breast cancer. On the basis of this ana-
lysis, we found that luminal CD133+, basal cell, and
stem cell enriched MECs were able to give rise to tu-
mors of both basal and luminal subgroups (Fig. 3),
with no correlation to tumor histology or ESR1 status
(data not shown). However, protein analysis of AKT,
SRC, and ERK did reveal a difference in AKT phos-
phorylation in the basal subgroup (Additional file 5, panel
b). Interestingly, the luminal CD133− population, which
is enriched in luminal progenitors [34], exclusively
Table 1 Description and summary of tumor histologies
Tumor histology Overall cellular
organization
Histology description Cytokeratin staining
Acinar Well differentiated Acini with bilayered, duct-like epithelial cells Maintenance of ductal morphology with K8 cells
surrounding clear lumens and K14 cells adjacent
to the stroma
Papillary Well differentiated Epithelial cell sheets, generally 2–3 layers thick,
surrounded by stroma
Maintenance of luminal and basal cell organization
with K14-positive cells adjacent to the stroma
Solid adenocarcinoma Poorly differentiated Multilayered epithelial cells grouped in large
units (>100 μm in diameter) surrounded by
1–2 layers of stromal cells
Primarily K8-positive with sparse K14-positive cells
near stromal regions
Squamous Poorly differentiated Adenocarcinoma with clusters of keratin
pearls and sheets of squamous epithelia
Large solid areas of either K8- or K14-positive cells;
K14 cells are localized near keratinized regions
Lipid-rich Poorly differentiated Heavily vacuolated epithelial cells Primarily K8-positive
Sebaceous-like Poorly differentiated Epithelial cells with enlarged nuclei and
foamy cytoplasms
Primarily K14-positive
Abbreviations: K8 keratin 8, K14 keratin 14
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established tumors within the basal subgroup. To deter-
mine the significance of this observation, we compared
the distribution of basal and luminal subgroups generated
from each cell population with the distribution we ob-
served when unsorted MECs were transduced with the
EF1α-PyMT-ZsGreen lentivirus [8]. Compared with un-
sorted MECs, the basal-restricted distribution of tumors
derived from luminal CD133− cells was statistically signifi-
cant (p = 0.017) (Additional file 6: Table S1). In contrast,
all other cell populations generated tumors of both basal
and luminal subgroups at a frequency similar to that of
unsorted MECs. These data demonstrate that the stem,
basal, and luminal CD133+ MEC populations can estab-
lish tumors that classify within either molecular subgroup,
whereas CD133− luminal cells preferentially establish tu-
mors of the basal subgroup.
Unsupervised hierarchical clustering of tumors gener-
ated from enriched MEC populations revealed two
major hierarchical tumor clusters, one composed of only
CD133− luminal tumors and another composed of tu-
mors generated from all MEC populations (Additional
file 7). Differential expression analysis comparing these
two major hierarchical clusters identified 1046 unique
genes showing at least twofold differential expression at
an adjusted p value <0.05 (Additional file 8: Table S2
and Additional file 9: Table S3). One gene of interest,
Sox11, was upregulated in tumors derived from luminal
CD133− MECs. Interestingly, Sox11 is a transcriptional
regulator upregulated in BRCA1-mutant breast cancers
and has been shown to promote cell survival and prolif-
eration in breast cancer cells [51].
Luminal CD133+ cells give rise to tumors that are
significantly less metastatic than other tumor groups
We investigated whether the enriched MEC populations
expressing PyMT could generate tumors with different
metastatic capacities. Metastasis was measured in mice
with similar tumor latency, tumor size (2 cm), and tumor
burden (single tumor). Similar to other PyMT-driven
models, primary tumors generated from each MEC popu-
lation metastasized to the lungs (Fig. 4a, b) [16]. Metasta-
ses to other organs were not detected. The metastatic
burden in lungs was quantified by whole mount fluores-
cent imaging and H&E staining of serial lung sections from
mice with similar tumor size and latency. Interestingly,
although no significant differences in tumor prevalence or
progression were observed between the four tumor-
initiating populations (Fig. 1d), tumors derived from the lu-
minal CD133+ cell population were significantly less meta-
static than all other tumor groups (Fig. 4c). Furthermore,
these cells formed significantly fewer lung tumor foci than
the other tumor groups (Fig. 4d); however, there was no
difference in the average area per metastatic focus (Fig. 4e).
To determine whether tumors with specific histologies
have different metastatic propensities, we examined
the numbers of metastases per tumor histology type
(Additional file 10, panels a–d). We did not find an asso-
ciation between metastatic propensities and histology
(Additional file 11). In addition, an association was not
observed between PyMT downstream activity and number
of metastases (Additional file 5, panel c). Taken together,
these data suggest that metastatic properties of a tumor
may be influenced by the tumor’s cellular precursor.
Fig. 3 Tumor microarray gene expression profiling. Tumors were analyzed by microarray gene expression profiling and hierarchically clustered
with mouse mammary tumor models using an intrinsic gene set identified by Herschkowitz et al. [7]. Vertical lines indicate individual tumors. Each
enriched mammary epithelial cell population is indicated by a different color: green = luminal CD133+; blue = luminal CD133−; red = basal;
black = stem cells. Mouse mammary tumor models that generate molecularly luminal tumors are shown in dark blue, and those predominantly
within the basal subgroup are displayed in dark red. Normal mouse mammary tissue is represented in brown (n = number of tumors). DMBA
7,12-dimethylbenz[a]anthracene, MMTV mouse mammary tumor virus, PyMT polyomavirus middle T antigen
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Metastasis progresses through several stages: Cells
leave the primary site and enter the bloodstream or lym-
phatics, survive within the circulatory system, exit the
circulatory system, and colonize a secondary site [52].
We next tested whether tumors derived from CD133+
cells were deficient in one or more steps of the meta-
static process. First, we quantified CTCs in mice bearing
primary tumors, which provides a measure of tumor cell
invasion and intravasation into the bloodstream. CTCs
expressing ZsGreen, a fluorescent protein coexpressed
with PyMT, were quantified in whole blood from tumor-
bearing mice by FACS and normalized to both the
volume of collected blood and background fluorescence
observed in non-tumor-bearing mice. Whole blood from
Fig. 4 Metastatic profiles of tumors generated from enriched mammary epithelial cell populations. a Representative bright-field (left panel) and
fluorescent (right panel) images of the same lung. Arrowheads indicate metastases (scale bar = 1 mm). b Representative image of hematoxylin and
eosin staining of a metastatic lung section. Arrows indicate metastases (scale bar = 1 mm). c Percentage of mice with lung metastases per tumor
group. Luminal CD133+ cell tumors were less metastatic than the other tumor groups (two proportion z test; n = number of mice). d Number of
metastatic lung foci per tumor group. Luminal CD133+ cell tumors generated fewer metastatic foci than the other tumor groups (Mann–Whitney
U test; median values shown). e Quantification of metastasis area per unique metastatic site in serial lung sections. No difference in size of tumor
metastasis was detected between the tumor groups (n = number of mice). f Normalized number of circulating tumor cells in mice with luminal
CD133+ tumors compared with all other tumor groups. ZsGreen signaling in whole blood isolated from tumor bearing mice was analyzed by
fluorescence-activated cell sorting and normalized to no-tumor control signal. Luminal CD133+ tumor-bearing mice had fewer circulating tumor
cells. Mice with non-metastatic tumors are represented by green, and those with metastatic tumors are represented by black (unpaired t test;
mean values shown; n = number of mice). g Quantification of the number of lung tumor foci per tail vein injection of metastatic luminal CD133+
tumor cells (tumor 1), non-metastatic luminal CD133+ tumor cells (tumor 2), or metastatic luminal CD133− tumor cells (tumors 3 and 4) (unpaired
t test; mean values shown; n = number of mice). Data shown in (a)–(e) represent spontaneous metastasis occurring from primary tumors, and
data shown in (f) are from non-spontaneous tail vein injection assays. *p < 0.05, **p < 0.01, ***p < 0.0005, ****p < 0.0001
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mice with luminal CD133+ cell transplants had signifi-
cantly fewer CTCs than the other tumor groups (Fig. 4f ).
Next, using a non-spontaneous metastasis assay, meta-
static colony formation was assessed following tail vein
injection of isolated tumor cells to evaluate their ability
to extravasate from the bloodstream and colonize sec-
ondary sites. When injected into the tail vein, tumor
cells derived from both luminal CD133+ and luminal
CD133− populations were able to colonize and prolifer-
ate within the lung, regardless of whether the donor
tumor was metastatic (Fig. 4g and Additional file 12).
These data suggest that luminal CD133+ cells give rise
to tumors with a limited ability to escape the primary
cancer and intravasate into the bloodstream.
Discussion
The PyMT oncogene has a broad capability to establish
a variety of tumor histologies and subtypes. Members of
the Li laboratory developed a model wherein a modified
avian leukosis sarcoma virus expressing PyMT (RCAS-
PyMT) was used to infect transgenic mice engineered to
express tva, the RCAS (replication competent avian sar-
coma leukosis virus LTR splice acceptor) receptor, on
different mammary cell types [53]. Intraductal infection
with RCAS-PyMT was performed in mice expressing tva
under the control of several promoters, including the
MMTV LTR and K6 promoter [27, 31]. When tumors
generated by the different models were compared, dis-
similar histological and molecular phenotypes were ob-
served. MMTV-tva/RCAS-PyMT tumors were acinar
and composed of luminal and myoepithelial cells, a
phenotype that contrasted with the papillary tumors
generated by K6-tva/RCAS-PyMT. These researchers
also showed that the molecular profiles of tumors gener-
ated by MMTV-tva/RCAS-PyMT, K6-tva/RCAS-PyMT,
and MMTV-PyMT were not similar, with the K6-tva
tumors having a unique profile similar to that of a
normal-like breast cancer subtype [27]. In an expanded
analysis of molecular profiles from the RCAS-PyMT and
MMTV-PyMT models, Hollern and Andrechek further
demonstrated significant diversity, particularly among
tumors derived from different mouse strains [40]. Taken
together, these data demonstrate that the PyMT onco-
gene has the capacity to generate several tumor subtypes
and that differences in the cellular context of the onco-
gene can affect tumor heterogeneity.
We have similarly observed a variety of histological
and molecular subtypes in tumors induced by the PyMT
oncogene. Previously, we showed that broad expression
of the oncogene in mammary epithelium, using the
EF1α-PyMT-ZsGreen lentivirus, generated late-stage
tumors consisting of both luminal and myoepithelial
cells, with a majority of tumors having acinar and solid
histology [12], which are similar features of tumors
established by the MMTV-tva/RCAS-PyMT model [53].
However, a notable difference between these models was
the appearance of squamous metaplasia, which was ob-
served in 30 % of the EF1α-PyMT-ZsGreen tumors, but
not in MMTV-tva/RCAS-PyMT tumors [12, 27]. This
tumor subtype is rare in the MMTV-PyMT model, with
a reported frequency of only 4–8 % [22, 40]. The data in
our present study expand upon those previous studies
by demonstrating that squamous metaplasia was ob-
served more frequently when basal and stem cell popu-
lations were infected with the EF1α-PyMT-ZsGreen
lentivirus. Similar data were obtained by Keller et al.
from studies performed with normal human breast cells.
They showed that transduction of CD10-enriched hu-
man basal cells with oncogenic lentiviruses resulted in
ER− and metaplastic tumors with squamous differenti-
ation. In contrast, epithelial cell adhesion molecule–
positive (Epcam+) luminal cells generated ductal
carcinomas with luminal features [54]. In addition, Ince
et al. showed that transformation of myoepithelial-like
human breast cells generated squamous carcinomas of
the breast, whereas luminal-like cells gave rise to adeno-
carcinomas [14]. Collectively, these studies provide
strong support that a cell within the basal lineage, either
a myoepithelial cell or a stem cell, is the origin of squa-
mous metaplasia in mammary tumors.
The ability to fractionate primary mouse mammary
cells into luminal, basal, and stem cell populations, and
their receptiveness to ex vivo manipulation and out-
growth following transplantation, provides a unique
method to study how cellular context affects oncogen-
esis [12]. In the present study, we investigated whether
tumor latency, histology, metastasis, and molecular sub-
type are altered when the PyMT oncogene is targeted to
distinct FACS-enriched mammary cell populations.
The data demonstrate that each MEC population is
able to generate tumors at similar latency and with
broad pathology. However, some cell populations
preferentially established distinct pathologies. Most
striking was that luminal CD133+ cells gave rise to a
higher proportion of tumors with papillary histology
and ESR1 expression and the lowest proportion of tu-
mors with squamous metaplasia. Consistent with their
well-differentiated pathology, tumors from luminal
CD133+ cells also produced fewer CTCs and metasta-
ses. An opposing phenotype was observed in tumors
generated by enriched stem cells. Notably, these cells
generated tumors that were ER−, exhibited squamous
metaplasia, and produced more CTCs and metastases
than luminal CD133+ cells. Thus, luminal CD133+
cells had a propensity to produce well-differentiated
tumors, whereas poorly differentiated and metaplastic
tumors were more commonly observed from enriched
stem cells.
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Although the MMTV LTR is expressed primarily in lu-
minal cells, it is also active broadly in basal, stem, and
luminal cell populations of the mammary gland [27, 29].
In the MMTV-PyMT model, the oncogene may target a
multipotent progenitor because clonal cell lines derived
from precancerous lesions can establish cell types ex-
pressing markers for both luminal and myoepithelial
populations [25, 55]. Histological and cellular heterogen-
eity are also observed in vivo in the MMTV-PyMT
model, particularly during precancerous development.
Early lesions are composed of both hormone receptor–
positive and hormone receptor–negative cells, with spor-
adic myoepithelial coverage [24]. As the tumors develop
to malignant lesions, they exhibit a loss of both hormone
receptor–expressing cells and myoepithelial cells [24]
and an expansion of cells double-positive for CD61 and
CD29 [26], markers that are coexpressed on normal lu-
minal progenitors. Some similarities between MMTV-
PyMT tumors and those derived from the luminal
CD133− cell population are evident. In particular, the
histopathology of tumors from this population was most
similar to that of tumors in the MMTV-PyMT mouse
model. Solid adenocarcinomas are seen in 60 % of
MMTV-PyMT tumors [22], and this was the dominant
histology in approximately 40 % of tumors derived from
the luminal CD133− cell population. However, tumors
established by luminal CD133− cells were classified as a
basal subgroup, whereas MMTV-PyMT tumors clus-
tered within the luminal subgroup [7]. The reason for
this discrepancy is unclear, but it may be a result of dif-
ferences in the developmental stage of cells targeted in
each model. The MMTV LTR is active at prepubertal
stages of mammary gland development [29], which sug-
gests that immature mammary epithelium is the origin
for MMTV-PyMT tumors. In contrast, the primary
MECs used for FACS enrichment in our study were
derived from postpubertal mice. These cells would
have had been exposed to the maturation effects of
systemic hormones, which may alter their lineage po-
tential. Recent studies have shown that oncogenic
stress can significantly increase the plasticity and multi-
lineage potential of differentiated MECs [56–58]. Both
the MMTV-tva/RCAS-PyMT and EF1α-PyMT-ZsGreen
models generate heterogeneous tumors consisting of
myoepithelial and luminal cell lineages, which contrasts
with the predominantly luminal cell type that is observed
in late-stage MMTV-PyMT tumors [59]. These data sug-
gest that tumor cells generated by the MMTV-PyMT and
virus-based models have differences in their lineage plasti-
city, particularly at more advanced stages of progression,
which may influence the molecular classification of tu-
mors. Further studies are necessary to assess the effect of
oncogenic stress on the lineage plasticity of MECs at pre-
and postpubertal stages of development.
Using the method described by Herschkowitz et al., we
categorized tumors derived from the sorted cell popula-
tions and 12 different mouse models of breast cancer
into 2 general molecular subgroups: basal and luminal
[7, 60]. These data demonstrate that both luminal and
basal tumor subgroups can arise from enriched luminal
CD133+, stem, and basal cell populations. However, we
also show that transformation of CD133− luminal cells,
which are enriched for luminal progenitors [34], gener-
ated tumors of the basal subgroup. This finding sug-
gests luminal progenitors preferentially establish basal
rather than luminal tumors. Consistent with this, sev-
eral recent observations attribute basal-like breast can-
cer to a luminal population. Lim et al. demonstrated
that the molecular profile of untransformed luminal
progenitors most closely resembles basal-like breast
cancers [8]. In addition, transformation of human
EpCAM+/CD10−/CD49f + luminal progenitors derived
from reduction mammoplasties established tumors
with features similar to basal-like breast cancer, in-
cluding reduced ESR1 and greater K14 expression than
tumors derived from differentiated luminal cells [54].
Furthermore, targeting Brca1 loss of function to lu-
minal cells in mice generated tumors with basal-like
features that closely resembled those observed in pa-
tients carrying the BRCA1 mutation. However, the
same loss of function in basal cells generated adeno-
myoepitheliomas [10, 15]. Taken together, these data
support luminal progenitors as a cellular origin of
basal-like breast cancer.
There are a number of challenges to studying how the
cell of origin influences tumor progression in breast can-
cer. These include the complexity of normal mammary
cell types from which a tumor may arise [60] and tech-
nical difficulties in precisely targeting oncogenes to spe-
cific cell types. As such, the data from this study should
be considered in the context of limitations of the ap-
proach used to target expression of PyMT to distinct cell
populations. For example, the cells that were trans-
planted represent enriched populations but not purified
cell types. Thus, a tumor phenotype cannot be credited
to a specific cell type. In addition, specific cell popula-
tions may have a transduction bias, as has been observed
between cultured luminal and myoepithelial cells, which
may limit the diversity of cell types targeted by the lenti-
virus [61]. Transduction of primary MECs with lentivi-
ruses and the subsequent expression of PyMT and
ZsGreen may also alter the sorting process. However,
maximum expression of lentiviral transgenes generally
takes several days. ZsGreen expression was observed in
only about 2 % of cells 24 h after transduction, and
PyMT protein expression was low at this time. Because
cell sorting and transplantation were performed within
24 h after the cells were exposed to virus, it is unlikely
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that expression of PyMT would have any significant in-
fluence on the populations before the sort. In addition,
the study was designed to ensure each sorted population
was exposed to similar conditions during the ex vivo
procedures. Primary cells were collected, transduced,
and sorted by FACS from a pool, and each population
was cotransplanted with 5–20-fold more uninfected, un-
sorted MECs, which would provide comparable in vivo
environments for tumor development. Thus, the main
variable was the cell population used to generate the
tumors.
Conclusions
We report that differentiated luminal (CD133+), luminal
progenitor (CD133−), basal, and stem cell enriched pop-
ulations have the capacity to give rise to mammary
tumors at equivalent frequency and latency when trans-
formed with PyMT oncogene. However, mammary cell
populations can produce tumors with differences in
histopathology, molecular classification, and metastatic
potential. Basal and stem cell enriched populations pre-
dominantly established poorly differentiated squamous
tumors, whereas differentiated luminal cells gave rise to
a high proportion of ER+ papillary tumors. We also
demonstrate that the luminal progenitor enriched popu-
lation specifically gives rise to tumors that cluster within
the basal molecular subgroup. Taken together, these data
demonstrate that targeted expression of PyMT in differ-
ent cell types affects tumor histology, molecular subtype,
and metastatic potential. In addition, the data provide
support that the cellular origin of squamous metaplasia
resides within the basal or mammary stem cell population.
Additional files
Additional file 1: Figure S1. Postinfection PyMT expression in cultured
total MECs. a Flow cytometric analysis of percentage of ZsGreen-positive
cells for 5 days post-EF1α-PyMT-ZsGreen infection (10,000 events,
mean ± SD, n = 3). b Quantification from simple Western blot analysis of
PyMT-HA expression over time in infected MECs and uninfected MEC
controls for 5 days following infection. PyMT-HA peak area was nor-
malized to GAPDH peak area. 293 T cells are shown as positive and
negative controls for PyMT-HA expression. c Multiplex simple Western
blot stained for hemagglutinin (HA) tag and GAPDH. Protein lysates
were prepared each day for 5 days following infection and PyMT-HA
(60 kDa) with 293 T positive and negative controls. HA tag and
GAPDH signals are shown with different exposure times. (TIFF 1824
kb)
Additional file 2: Figure S2. Hormone independence of EF1α-PyMT-
ZsGreen-transduced MEC tumors. a Half-maximal inhibitory concentration
values of wild-type MECs and cells isolated from luminal CD133+, lu-
minal CD133−, basal, and stem cell tumors treated for 48 h with 4-
hydroxytamoxifen (4-OHT). No significant differences among the viability of
tumor cells and normal MECs were observed after 4-OHT treatment (t test).
b Assessment of tumor growth response to ovariectomy. Transduced
primary cells were transplanted into ovariectomized mice to test if lack of
hormone signaling would result in reduced tumor growth from lu-
minal CD133+ cells. No differences in tumor latencies were observed
among tumor groups (n = number of mice). (TIFF 1112 kb)
Additional file 3: Figure S3. PyMT expression and activity in tumors.
a RT-qPCR quantification of relative PyMT mRNA expression levels in
individual MMTV-PyMT, luminal CD133+ cell, luminal CD133− cell, basal cell,
and stem cell tumors normalized to the Rplp0 housekeeping gene. Analysis
was performed in triplicate for each tumor sample. b Western blot
quantification of relative ratio of pAKT to AKT protein expression in individual
MMTV-PyMT, luminal CD133+ cell, luminal CD133− cell, basal cell, and stem
cell tumors normalized to β-actin. cWestern blot quantification of relative ratio
of pERK to ERK protein expression in individual MMTV-PyMT, luminal CD133+
cell, luminal CD133− cell, basal cell, and stem cell tumors normalized
to β-actin. d Western blot quantification of relative ratio of pSRC to
SRC protein expression in individual MMTV-PyMT, luminal CD133+
cell, luminal CD133− cell, basal cell, and stem cell tumors normalized
to β-actin. (TIFF 2407 kb)
Additional file 4: Figure S4. Percentage of tumors with a dominant
histology. Each tumor was classified based on the histological feature
representing at least 50 % of the tumor area. Tumors classified as mixed
did not have a dominant histological type. Tumors derived from stem
cells were significantly more squamous than tumors derived from luminal
CD133+ and CD133− luminal cells (two proportion z test, n = number of
tumors). (TIFF 833 kb)
Additional file 5: Figure S5. PyMT activity comparison with tumor
histology, molecular subtype, and metastasis. a Western blot quantification
of relative ratio of pAKT to AKT, pERK to ERK, and pSRC to SRC protein
expression in enriched population tumors segregated based on tumor
histology and normalized to β-actin. No significant differences in protein
expression were detected among tumor groups (t test, n = number of
tumors). b Western blot quantification of relative ratio of pAKT to AKT,
pERK to ERK, and pSRC to SRC protein expression in enriched population
tumors segregated based on tumor molecular subtype and normalized
to β-actin. Molecularly basal tumors exhibited significantly higher
levels of pERK/ERK levels than luminal tumors (t test, p value shown,
n = number of tumors). c Western blot quantification of relative ratio
of pAKT to AKT, pERK to ERK, and pSRC to SRC protein expression in
enriched population tumors segregated based on tumor metastasis
and normalized to β-actin. No significant differences in protein expression
were detected among tumor groups (t test, n = number of tumors).
(TIFF 1046 kb)
Additional file 6: Table S1. Distribution of basal and luminal subtypes.
Distribution of basal and luminal tumor subtypes generated by EF1α-
PyMT-ZsGreen lentiviral transduction of each sorted cell population as
compared with the distribution obtained from EF1α-PyMT-ZsGreen-
transduced but unsorted MECs [8], using Fisher’s exact test. (DOCX 14 kb)
Additional file 7: Figure S6. Unsupervised hierarchical clustering of
tumors generated from enriched MEC populations. Tumor cell of origin,
histology, metastatic propensity, and molecular subtype are indicated
below the dendrogram cluster. (TIFF 1486 kb)
Additional file 8: Table S2. Top 100 unique differentially expressed
genes in the luminal CD133− tumor cluster compared with the mixed
tumor cluster. Group 1 is the mixed tumor cluster, and group 2 is the
luminal CD133− tumor cluster. A t test was performed on Benjamini–
Hochberg-corrected, log-transformed data. Table includes gene name,
ratio, p value, and direction. (XLSX 14 kb)
Additional file 9: Table S3. All differentially expressed genes in the
luminal CD133− tumor cluster compared with the mixed tumor cluster.
Group 1 is the mixed tumor cluster, group 2 is the luminal CD133− tumor
cluster. A t test was performed on Benjamini–Hochberg-corrected,
log-transformed data. Table includes gene name, ratio, p value, and
direction. (XLSX 73 kb)
Additional file 10: Figure S8. Number of metastases per tumor
histology. Histological area per tumor derived from luminal CD133+
cells (a), luminal CD133− cells (b), basal cells (c), and stem cells (d),
as well as the number of metastatic foci detected in the lungs of
the mice bearing each of the tumors (shown as red values above
each tumor). (TIFF 1562 kb)
Additional file 11: Figure S9. Quantification of the number of
metastases per tumor histology. A histology was assigned to a tumor
when the histology comprised at least 50 % of the tumor area. Tumors
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that had mixed histologies were classified as mixed. No statistically
significant differences in the metastatic propensities among histological
tumor types were observed (Mann–Whitney U test). (TIFF 654 kb)
Additional file 12: Figure S7. Enriched MEC populations metastasize
to lung. Representative fluorescence images of lungs from mice that
received tail vein injections of metastatic luminal CD133+ tumor cells
(tumor 1), nonmetastatic luminal CD133+ tumor cells (tumor 2), or
metastatic luminal CD133− tumor cells (tumors 3 and 4). Lungs were
examined 3 weeks after the tail vein injection. Fluorescent black-and-white
lung images were false-colored green in ImageJ software and overlaid on a
black background. (TIFF 2284 kb)
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